The deal hands AbbVie a drug that’s shown early promise in multiple myeloma and may be useful treating other cancers and ...

The biotech is taking inspiration from cystic fibrosis treatment and applying a similar approach to developing "corrector" and "potentiator" medicines for the kidney disease.

A slower ramp-up of Kisunla dosing lowers the rate of dangerous brain swelling, a risk that has made doctors reluctant to ...